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identifying the key toxic players within an in-vivo toxic syndrome is crucial to develop targeted 
therapies. Here, we established a novel method that characterizes the effect of single substances by 
means of an ex-vivo incubation set-up. We found that primary human spermatozoa elicit a distinct 
motile response on a (uremic) toxic milieu. Specifically, this approach describes the influence of a bulk 
toxic environment (uremia) as well as single substances (uremic toxins) by real-time analyzing motile 
cellular behavior. We established the human spermatozoa-based toxicity testing (HSTT) for detecting 
single substance-induced toxicity to be used as a screening tool to identify in-vivo toxins. Further, we 
propose an application of the HSTT as a method of clinical use to evaluate toxin-removing interventions 
(hemodialysis).
An in-vivo toxicity situation is observed in end-stage kidney disease (ESKD) which significantly contributes to 
morbidity and mortality of these patients1. During the progressive loss of kidney function, uremic substances, 
that would normally be excreted by the healthy kidney, accumulate in-vivo2,3. This leads to a myriad of clinical 
symptoms coined as the uremic syndrome4 and subsequent death, unless hemodialysis (HD) is initiated5. A thor-
ough understanding of the biological activity of uremic substances is crucial to unveil mechanisms behind the 
uremic syndrome.
To investigate the biochemical impact of substances, animal models or cell cultures can be applied6–9. 
Compared to animal models, human in-vitro models are more consistent in predicting clinical outcome10,11 and 
more suitable for identifying mechanisms relevant for in-vivo toxicity12. Recently developed organ-on-a-chip 
models underline the potential of human-derived system6,11,13,14 but a lack of primary cell material and the com-
plexity of recreating a toxic environment in the chip-system limits its application for broad toxicity testing. As 
an alternative, we established a cellular method derived from an available human cell source in order to mimic a 
toxic in-vivo situation.
Human spermatozoa are a neglected primary cell type of study, however, there is abundant cellular material of 
human spermatozoa that can be gained from fertile men. Due to the specific function to fertilize an oocyte, sper-
matozoa have adapted cellular characteristics. E.g. transcriptomic and translational activity are virtually absent in 
spermatozoa15,16 and thus, cell function is mainly regulated on protein level. Hence, due to the inability to produce 
proteins, spermatozoa rely on the environment for external regulation17,18.
By means of mass spectrometry, the proteome of human spermatozoa has been thoroughly characterized19–21. 
Most recent advanced high-throughput proteomic approaches resulted into the identification of around 6000 pro-
teins expressed by human spermatozoa22,23, wherein redundant pathways of energy metabolism (carbohydrates, 
lipids, proteins) and apoptosis were significantly represented16,24. This makes spermatozoa a functionally defined 
cell type that strongly resembles the energy apparatus that maintains the cell survival of the human body25. These 
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cellular characteristics are ideal for the investigation of substances causing specific effects on the metabolism and 
the proteomic stability of the cells.
Intriguingly, uremic men have reduced fertility and sperm quality that is assumed to be due to abnormali-
ties of endocrine factors26, however toxic effects of external uremic toxins cannot be excluded. In line with this, 
progressive motile function of spermatozoa is impaired in ESKD compared to earlier stages of chronic kidney 
disease27.
Progressive motility defines the capacity of sperm to efficiently move which is required for male fertility28. 
Motile function of human spermatozoa is energetically highly conserved by the ability to switch between mito-
chondrial oxidative phosphorylation and glycolysis upon the availability of oxygen and substrates17,29,30. In 
contrast to progressive motility, directional motility (chemotaxis) of spermatozoa is induced by cell-specific 
differentiation stimuli in-vitro31,32. Thus, progressive motility of spermatozoa can be maintained in-vitro that is 
non-directional and robust against slight environmental alterations but, as we hypothesized, sensitive for in-vivo 
toxins. To investigate ex-vivo spermatozoon function, motility can be observed via light microscopy33 which 
facilitates the implementation into an applicable test system.
Uremic toxins reported in the literature have been recently summarized and thereby, the level of evidence has 
been scored revealing defined organ systems affected by distinct substances9. Here, we present an approach that 
defines toxicity by comparing the effect of many substances within one single cell model. The precise aim of this 
study was to develop a bio-assay that can be used to analyze toxicity of biological substances in an in-vitro setting. 
Due to the spermatozoon source of the cell model, this may give additional guidance to the identification of toxins 
that interfere with male fertile function in ESKD.
In a first step, we set up an ex-vivo incubation profile of spermatozoa to measure changes in motile function. 
Second, we screened on the sensitivity of the in-vitro model for a bulk uremic milieu. Third, we screened on the 
sensitivity of the in-vitro model for single uremic substances and drugs. Fourth, we applied the newly established 
human spermatozoa-based toxicity testing (HSTT) to estimate the removal of toxins during an intervention such 
as hemodialysis in ESKD patients.
This effort represents a joined initiative of the European Uremic Toxin Work Group (EUTox) that is dedicated 
to the identification of novel toxins in the field of uremic toxicity. Here, we describe the precise establishment 
of a feasible human-specific in-vitro tool to unveil toxins potentially relevant for many fields. Knowledge about 
identified toxins may be used to improve treatment of a toxic syndrome by a specific toxin-targeting approach.
Results
establishment of an in-vitro motility analysis of human spermatozoa. To establish the human 
spermatozoa-based toxicity testing (HSTT), we set up a method to preserve spermatozoa ex-vivo. Standardized 
clinical methods estimate motile function as an indicator of male fertility34. For this, WHO guidelines recom-
mend a snap-shot discrimination into progressively motile, non-progressively motile and immotile cells28,34. This 
allows a clinical analysis of motile function but is, however, not suitable for kinetic assessment of sperm motility 
over time. To overcome this, a previously used method35 was translated into a clinically applicable tool for toxicity 
testing (Fig. 1a). First, our goal was to set up a precise analysis of human spermatozoa in non-toxic conditions by 
means of camera-integrated light microscopy (see methods). For this, ex-vivo incubation of spermatozoa was per-
formed to investigate motile function. To evaluate the precision of single time-point analyses within the model, 
duplicate measurements were performed. Here, we found minor changes between two motility measurements 
Figure 1. Analysis of motility and survival capacity of spermatozoa ex-vivo. (a) Assessment of progressively-
motile spermatozoa. Dashed, bold line in Bürker chamber indicates the crossing mark for motile cells. (b) 
Defining precision of single-measurement analysis of motile cells. Two dots at each time point show duplicate 
analysis of one sample. Six donors at three points measured in independent experiments. (c) Kinetic assessment 
of motile function in comparison to survival. Cells analyzed at six time points for motility and thereafter, at one 
time point for survival. Dots represents mean of six different donors. P-value indicates significance level.
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of a single sample (difference in motility counts at 60 min 3.6% ± 1.1%, at 120 min 2.5% ± 1.7% and at 210 min 
2.6% ± 1.8%) (Fig. 1b). Further, we kinetically analyzed motility function and compared it to the viability of sper-
matozoa. We could detect linearly decreasing but sustained motile function over time (55.6% ± 24.2% of initial 
motility after 210 min) (Fig. 1c). In addition, baseline survival was maintained at a significantly higher level over 
time than baseline motility (77.2% ± 25.4% of initial survival; p = 0.03) (Fig. 1c). In summary, we established a 
feasible ex-vivo method that precisely estimates the decline of motile human function over time. Thereby, viability 
of spermatozoa can be preserved.
Detecting toxicity of uremic ultrafiltrate (UUF). Next, the HSTT was applied to detect toxicity of the 
uremic milieu (Fig. 2a). For this, we accessed uremic ultrafiltrate (UUF) from ESKD patients. UUF has been 
previously studied as a model of uremic toxicity36. Here, we identified a dose-dependent decrease of motility of 
human spermatozoa when incubated with bulk UUF for one minute (high concentration: 32.0 ± 6.3 vs. low con-
centration: 42.9 ± 11.1 motile cells/minute, p = 0.03). However, we could not find a significant dose-dependent 
effect on viability (high concentration: 72.2% ± 9.1% vs. low concentration: 71.1% ± 8.4% of viable cells, p = 0.03) 
(Fig. 2b). To investigate toxic effects over time, incubation time was extended. Here, we found a complemen-
tary dose-dependent decrease of motile function after 120 min (−16.2% ± 30.6%, p = 0,002) and 210 min 
(−10.5% ± 21.0%, p = 0.02) of incubation, respectively. After 340 min, the cell model could not significantly dis-
criminate between high and low concentrations of UUF (Fig. 2c). This implicates a sensitive time range of the 
cell model. Further, we tested whether the cells are sensitive for hydrophobic or hydrophilic characteristics of the 
uremic milieu. For this, elution through a preparative reversed phase column was applied to separate the UUF 
into six fractions. Within the UUF-fractions, fraction 1 is characterized as the most hydrophilic and contrast-
ingly, fraction 6 as the most hydrophobic part. In a kinetical manner, UUF-fractions were compared for toxicity 
on motile function. Here, we found lower motility induced by fractions 2–5 compared to the non-toxic control 
(−21.6% ± 4.1%; p < 0.05). However, we could not detect significant functional alteration induced by the most 
hydrophilic fraction 1 (−3,8% ± 22.4; p > 0,05) and the most hydrophobic fraction 6 (−3.9% ± 29.0; p > 0.05) 
(Fig. 2d), respectively. We conclude that the established in-vitro model is sensitive for changes of uremic concen-
tration derived from specific fractions within the UUF.
Figure 2. Toxicity detection of uremic ultrafiltrate (UUF). (a) Workflow of two experimental approaches. 
UUF collected from patients during high-flux hemodialysis and prepared by elution into fractions (F). F1 
is most hydrophilic and F6 most hydrophobic fraction, respectively. (b) High (1:1 dilution of UUF) and low 
concentration (1:16 dilution of UUF) of bulk UUF were applied in nine independent experiments for viability 
testing and 12 independent experiments for motility testing. Cells were gained from one donor and incubated 
for one minute. Two controls (w/o) were applied. (c) High and low concentration of UUF tested on motility 
long-term outcome. 12 independent experiments on cells from two donors, respectively. For each donor, two 
independent controls were applied (w/o). (d) Fractions (F1-F6) tested for toxicity by comparing high (red) vs. 
low (black) concentration after 120, 210 and 340 minutes of incubation. Mean shows two experimental series 
on cells from two donors on two conditions (high and low), respectively. Doubled controls were applied for 
each series (w/o, blue). Tickled line shows medium value of internal control. Bars in (d) present SEM. P-value 
indicates significance level.
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Detecting toxicity of a uremic toxin mix and drugs. In a next step, the HSTT was used to screen for 
toxicity of a uremic substance mix (Fig. 3a). For this, we generated a uremic toxin mix (UTM) based on purine 
derivatives (uric acid, xanthine, uridine, uracil) that were previously shown to co-elute with early fractions of the 
UUF36. Serum concentrations of uremic toxins were applied according to the EUTox database that includes 130 
uremic substances37. For each toxin, the highest serum concentration reported in uremic patients was installed to 
the in-vitro system and referred to as maximum concentration (Cmax)3. Here, we incubated the cells with the UTM 
to evaluate effects on sperm viability and motility. Strikingly, we found a dose-dependent decrease of motility 
induced by the UTM. In addition, viability of the cells was diminished by diluted UTM (UTM: 37.0% ± 30.4% 
vs. w/o: 74.8% ± 7.8%, p = 0.02). When Cmax of the UTM was applied, motile function was completely abolished, 
however, a fraction of cells survived (12.2% ± 15.1%) (Fig. 3b). This implicates that motile function is more sen-
sitive for toxicity, whereas viability can be better maintained in the same toxic condition. In a kinetical manner, 
we could confirm a stringent dose-dependent effect on motility and survival by the UTM (Fig. 3c,d). Further, we 
found specifically uracil within the UTM to be toxic on the cells (Suppl. Fig. 2). Next, we tested in-vitro toxicity 
of the diuretic drug furosemide that is commonly administered to ESKD patients38. For this, furosemide was 
installed to the cell model and tested for toxic effects. Here, we found a dose-dependent decrease of motility 
by furosemide (w/o: 72.2% ± 14.2%; Clow: 66.9% ± 18.2%; Cnorm: 60.5% ± 13.6%; Chigh: 40.3% ± 1.1%; p = 0.03) 
(Fig. 3e). However, no effect of furosemide on cell survival was observed (data not shown). We conclude that 
the HSTT can be applied to detect toxicity from a mix of uremic substances such as the UTM. In addition, clini-
cally relevant medication can be likewise investigated on potential toxicity.
Detecting toxicity of single uremic substances. In a next step, we applied the HSTT to previously 
denominated uremic toxins (UT). The UT can be separated into three classes along their physico-chemical 
characteristics: small water-soluble compounds (SWS), protein-bound substances (PB) and middle molecules 
(MM)39. To our knowledge, there is no study comparing multiple substances from all classes within one cell 
model. To establish this concept, we analyzed 47 UT (Table 1) derived from all three classes via the motility 
and survival assays of the HSTT (Fig. 4a). Here, we found most profound toxic effects from substances of the 
protein-bound class (change in function; PB: −10.0% ± 21.1%, SWS: 1.8% ± 26.3%; MM: 5.0% ± 19.0%) (Fig. 4b). 
In line with this, toxic effects by protein-bound substances have been described40. Specifically, we identified toxic 
effects by the substance group of cresoles and indoles (# 28–33); e.g. p-cresyl sulfate (#33) and indoxyl sulfate 
(#32) (Fig. 4c). Toxicity by these substance groups is confirmed by a recent meta-analysis on UT9. Further, we 
could discriminate toxic (e.g. p-cresyl sulfate, #33) from non-toxic substances (e.g. leptin, #18) in every sub-
stance class, respectively (number of toxic substances/total substances in class; PB: 12/16, SWS: 11/17; MM: 5/14). 
In addition, we found that motility and viability were likewise abolished by toxic substances (#15–17, 31–32, 
46–47). By this approach, we confirm the toxicity of known UT and further, we can discriminate toxic from 
non-toxic uremic substances. Serial application of the HSTT may enable the identification of novel candidates 
that contribute to the uremic syndrome.
Figure 3. Toxicity detection of substance mix and drug. (a) Workflow to measure effects of a substance mix 
and drugs. Uremic toxin mix was applied in Cmax (highest concentration measured in uremic patients) and in 
Clow (1:16 dilution of Cmax). Following substances and concentrations were applied within the UTM: Uric acid 
(Cmax: 147 µg/ml; Clow: 9.19 µg/ml), xanthine (Cmax: 3.44 µg/ml; Clow: 0.22 µg/ml), uridine (Cmax: 32.6 µg/ml; Clow: 
2,04 µg/ml) and uracil (Cmax: 0,45 µg/ml; Clow: 0.03 µg/ml). (b) Survival (left) and motility (right) were analyzed 
after 120 minutes of incubation on a minimum of 3 donors. (c) Motility analysis of five experimental rounds. 
Cells from three different donors. (d) Frequency of viable cells over time on cells from three donors. In (c) and 
(d) SEM are shown. (e) Furosemide was applied to the cell model to test for motility. Incubation of 120 minutes 
was performed.P-value indicates significance level.
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Estimating toxin-removal by hemodialysis. Next, we aimed to assess toxin removal by hemodialysis 
(HD) treatment. For this, we accessed serum from six ESKD patients (Table 2) that was drawn pre-HD and 
post-HD, respectively. A paired analysis via the HSTT allows an estimate whether HD procedure improves serum 
toxicity in the patient (Fig. 5a). Via the staining method, dead Eosin+ cells could be identified in pre-HD serum 







guanidine µg/l 800 guanidines 0.00067797 1 SWS
malondialdehyde µg/l 769.6 aldehydes 0.00541972 2 SWS
1-methyladenosine µg/l 216.4 ribonucleosides 0.00006418 3 SWS
taurocyamine µg/l 121.8 guanidines 0.05000000 4 SWS
methylguanidine µg/l 1820 guanidines 0.00207763 5 SWS
cytidine µg/l 1263.6 purines 0.00027000 6 SWS
urea g/L 4.6 other 0.25000000 7 SWS
orotidine mg/l 47.2 pyrimidines 0.16666667 8 SWS
N-acetylarginine µg/l 4580 guanidines 0.01060185 9 SWS
uric acid mg/l 146.7 purines 0.21830357 10 SWS
SDMA µg/l 1232.2 guanidines 0.00305000 11 SWS
1-methylguanosine µg/l 89.2 ribonucleosides 0.00002503 12 SWS
oxalate mg/l 7.6 other 0.16666667 13 SWS
uracil µg/l 448 purines 0.00033333 14 SWS
hypoxanthine mg/l 5.3 purines 0.01948529 15 SWS
guanidinoacetic acid µg/l 693.8 guanidines 0.00296496 16 SWS
beta-guanidinopropionic acid µg/l 65.4 guanidines 0.00024962 17 SWS
leptin µg/l 490 peptides 0.16666625 18 PB
kynurenine µg/l 952.6 indoles 0.00228990 19 PB
kynurenic acid mg/l 9.5 indoles 0.02513228 20 PB
methylglyoxal µg/l 146 AGE 0.16666663 21 PB
phenyl sulfate mg/l 1.6 phenols 0.01666667 22 PB
2-methoxyresorcinol µg/l 322 phenols 0.16666625 23 PB
3-deoxyglucosone mg/l 3.5 AGE 0.16666625 24 PB
homocysteine mg/l 26.4 amino acid 0.25000000 25 PB
p-OH-hippuric acid mg/l 31.5 Hippurates 0.08076923 26 PB
putrescine µg/l 132 Polyamines 0.00007500 27 PB
indoxyl glucuronide mg/l 3.87 indoles 0.01666667 28 PB
p-cresyl glucuronide mg/l 5.1 cresoles 0* 29 PB
phenyl glucuronide mg/l 1.6 phenols 0.00166667 30 PB
indoxyl sulfate mg/l 236 indoles 0.01666667 31 PB
p-cresol mg/l 40.7 cresoles 0.18750000 32 PB
p-cresyl sulfate mg/l 5.1 phenols 0.01666667 33 PB
IL−6 ng/l 328.1 cytokines 0.16666667 34 MM
hyaluron µg/l 1843 peptides 0.00003686 35 MM
IL-1ß ng/l 1700 cytokines 0.16666663 36 MM
ß-endorphin ng/l 492 peptides 0.00000001 37 MM
neuropeptide Y ng/l 115.9 peptides 0.00000001 38 MM
K-Ig light chain mg/l 287 peptides 0.25000000 39 MM
retinol binding protein mg/l 369.2 peptides 0.00000001 40 MM
adrenomedullin ng/l 81.2 peptides 0.00000007 41 MM
TNF-α ng/l 408 cytokines 0.00000001 42 MM
endothelin ng/l 129.4 peptides 0.00000002 43 MM
atrial natriuretic peptide ng/l 436.6 peptides 0.00000071 44 MM
L-Ig light chain mg/l 328 peptides 0.00656000 45 MM
complement factor D mg/l 26 peptides 0.00054737 46 MM
cholecystokinin ng/l 131.5 peptides 0.16625000 47 MM
Table 1. List of uremic toxins tested. Cmax indicates applied concentration. NaCl or H2O were used as solvents. 
Solvent fraction defines remaining volume (V) of solvent in-vitro (by the ratio: Vsolvent/Vtotal). PBS was used 
to dilute. UT = uremic toxins. SWS = small water-soluble compounds, PB = protein bound, MM = middle 
molecules. AGE = advanced glycation end products. *Directly solved by PBS.
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(Fig. 5b). In general, cells exposed to non-treated (pre-HD) serum had lower motility compared to cells exposed 
to treated (post-HD) serum (−8.6% ± 10.5%, p = 0.03) (Fig. 5c). Analogously, a significant decrease of viability 
of cells was detected when cells were exposed to pre-HD serum compared to post-HD serum (−17.8% ± 22.7%, 
p = 0.03) (Fig. 5c). In the motility analysis, sera from 5/6 patients were more toxic pre-HD compared to post-HD. 
Solely in HD-treated patient #3 the opposite effect was observed. In the survival analysis, sera from 6/6 patients 
were more toxic pre-HD compared to post-HD (Fig. 5d). This indicates that either method discriminates pre 
versus post-HD serum. Further, we found that patients #1 and #5 were detected to have most toxic pre-HD serum 
compared to all other patients, as indicated by motility and survival readout, independently. Thus, we conclude 
that the HSTT can be applied to evaluate the presence of biologically active substances and further, the HSTT has 
the potential to assess the efficacy of toxin removal by treatments such as hemodialysis.
Discussion
Via the human spermatozoa-based toxicity testing (HSTT) multiple substances of a toxic syndrome can be com-
pared within one experimental set-up. Specifically, we propose motility testing of human spermatozoa as a highly 
sensitive tool to screen for in-vivo relevant uremic toxins. This is illustrated by a defined and dose-dependent 
motile response on uremic ultrafiltrate from ESKD patients, by a distinct single-substance response on previously 
denominated uremic toxins and eventually, by a sensitive detection whether serum from ESKD patients was 
detoxified by hemodialysis. In addition to this, survival analysis can be applied to identify very toxic substances 
and to define sublethal concentration of a toxin.
In-vivo, several organ systems are affected by the uremic state which requires experimental studies on vari-
ous cell types in-vitro2,39,41. This has prompted strategies to systematically cover experimental studies on uremic 
toxin-induced effects9. However, experimental tools that compare multiple substances, in a serial manner, remain 
scarce. Via the HSTT, a broad number of substances can be studied and eventually, ranked according to toxicity. 
This may add guidance to identify single toxins within the complex nature of the uremic syndrome. Within the 
toxin screen, the effect of equimolar concentration of salt as control was not studied and should be mentioned 
as drawback of this study. Future studies evaluating the toxicity of single compounds in depth should include a 
salt-control condition.
The HSTT is based on a feasible cell counting technique that can be applied to standard lab procedures. We 
found ex-vivo accessed spermatozoa from healthy young men as highly functional starting material in our exper-
iments. Recent improvements in freezing procedures of human spermatozoa for in-vitro fertilization42 will help 
to establish a standardized one donor-derived test kit for the HSTT, analogously. Based on our data, we propose 
healthy donors with viable cells that exert a baseline motility of 40 counts/minute as feasible donors for a kit.
Clinical symptoms that arise from a toxic syndrome - such as uremia - are vaguely understood4 and 
toxin removing strategies - such as hemodialysis – show inter-individual differences in improving uremic 
Figure 4. Toxicity detection of denominated uremic toxins (UT). (a) Workflow to measure effects of single 
substances (S1-Sx). (b) 47 UT tested for influence on motility (after 90 minutes of incubation) and survival (after 
300 minutes of incubation). UT are assigned to the three bio-chemical classes (small water-soluble compounds 
(SWS), protein bound (PB), middle molecules (MM)). Data are shown as relative change to non-toxic 
control. M1 and M2 represent two separate experimental motility rounds, V represents mean viability of six 
experimental rounds. Bold lines mark UT with reduced motility <25%, dashed lines mark UT with increased 
motility >25%. Marked UT are displayed in (c). Left: all UT with toxic effect, right: all UT with non-toxic effect. 
At least two separate experimental rounds are shown. Incubation was performed for 90 minutes.
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symptoms43–45. For now, KT/Vurea-dosage is clinically applied to quantify dialysis time. We suggest that the HSTT 
may help to individually prescribe dialysis time. Hypothetically, this may result in improved symptom relief after 
treatment.
The data in the present study also imply that uremic substances may interfere with spermatozoon function 
in-vivo. Since male fertility is lowered in uremic men26, the HSTT may help to identify responsible substances for 
this effect. Eventually, this assay can be applied to compare semen from healthy versus semen from uremic men 
in further studies.
To this end, described effects by the HSST need to be confirmed by further cell models and HSST-identified 
toxins need to be confirmed by clinical studies. Here, all experiments were performed according to standardized 
guidelines published by the EUTox initiative34 that allows for comparative trials.
Methods
Donation and ethical approval. The Local Ethical Committee at Umeå University, Sweden approved this 
study (§268/01, dnr 01-255). In addition to this, we confirm that all experiments were performed in accord-
ance with relevant regulations and guidelines for experimental studies on uremic toxins41. Semen samples were 
obtained after informed consent from 15 healthy human donors (21–30 years) without acute or chronic diseases, 
and medication free. Sexual continence before donation was not restricted. Serum samples were obtained from 




























P1 man 71 DM type 1 (since 10 y age) 1 4 h × 4 FX1000 HDF 20 48 17.3 4.1 732 72 2.5
P2 man 72 Nephrosclerosis 0 4 h × 3 FX100 HDF 0 32 18.3 4.8 748 70 0.9
P3 man 85 Nephrosclerosis 2 4 h × 3 FX80 HD 0 52 21.0 5.8 634 86 1.3
P4 man 58 Hereditary polycystic kidney disease 3 4 h × 3 FX100 HD 0 55 18.2 4.8 874 54 2.5
P5 woman 77 Hydronephrosis, Kidney stones 4 3.5 h × 2 FX80 HD 0 31 12.5 3.2 564 74 0
P6 woman 50 DM type 1 (since 6 y age) 1 4 h × 2 FX1000 HDF 15 37 13.5 4.1 432 86 0
Table 2. Patient characteristics of the patients included in the study. Details about hemodialysis procedure are 
shown. DM = diabetes mellitus, HD = hemodialysis, HDF = hemodiafiltration. UF = ultrafiltration. Urea in 
mmol/l. Creatinine in µmol/l. Vintage summarizes overall HD-time.
Figure 5. Detection of toxin-removal by hemodialysis. (a) Sera from six hemodialysis (HD) patients were 
taken pre and post HD. Incubation procedure was performed with human spermatozoa. (b) Staining of one 
representative experiment. Eosin+ dead cells stained red. White cytoplasm indicates viability. (c) Motility counts 
per minute and viability of cells after 120 minutes of incubation with pre- and post-HD serum, respectively. 
Violin plots summarize six HD patients measured in two separate experimental runs. (d) Patient-specific 
outcome on motile function (left) and viability (right). Individual patients (n = six) are displayed separately. For 
clinical data see Table 2. P-value indicates significance level.
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Semen preparation. Human semen was accessed in a sterile container and directly incubated for 15 min 
at 37 °C for liquefaction34. Thereafter, semen was investigated for microscopic abnormalities (e.g. azoospermia) 
and to this end, no abnormal signs were observed (0/15). For the in-vitro set-up, semen samples were transferred 
to two ml polypropylene tubes (Sigma-Aldrich, Saint Louis, USA) and after transfer softly mixed for five sec to 
homogenize. All further incubation procedure was performed at 37° with minimum volume of 200 µl.
Progressive motility investigation. Motility-based readout and controls. We transformed a previously 
described protocol35 to apply within an in-vitro culture readout with real-time analysis. Ten µl semen was injected 
into a disposable Bürker cell-counting chamber (DHC-B01, NanoEnTek, Digital Bio Technology Co., Inc., Seoul, 
Korea). Camera-integrated light microscopy (Carl Zeiss Microscopy, Jena, Germany) was performed with 400x 
magnification and 125–200 ms interval between two images. Recording time per sample was one minute and sub-
sequently, images were used for post-experimental analysis. For this, a single line of 0.20 mm within the Bürker 
chamber was utilized as a crossing mark for counting (bold line in Fig. 1a). Every spermatozoon crossing this line 
was counted. If baseline motility exceeded 60 counts per minute, we diluted the semen with buffer (1 part semen 
to 1 part buffer). In most cases, 1:1 dilution was sufficient to proceed with the analysis. Thereby, we preserved 
seminal plasma in the system to maintain baseline stimulatory effect on the semen35. However, we did not apply 
(serum) albumin as control, as this may interfere with the metabolism of spermatozoa46,47. Instead, following 
buffers were tested for dilution: phosphate-buffered saline solution (PBS, Dulbecco’s Phosphate Buffered Saline, 
Thermo Fisher Scientific, USA), Krebs Ringer bicarbonate solution (KRB, Sigma-Aldrich, Saint Louis, USA), 
Ringer acetate solution (RA, Braun, Danderyd, Sweden), peritoneal dialysis solution with 1.36% glucose (PDS, 
Physioneal 35®, Baxter, Deerfield, USA) and saline (NaCl). After dilution, the mean starting motility was 40 cells/
min (Suppl. Fig. 1a). PBS preserved motile capacity in-vitro (Suppl. Fig. 1b) and hence, PBS was applied for semen 
dilution and for substantial dilution of toxin reagents (Table 1). For analysis, Zeiss microscopy software (Zen 
2012, Carl Zeiss Microscopy, Jena, Germany) was used.
Correction for time. Before incubation, baseline motility of two different samples was analyzed. This created a 
mean starting baseline. Consecutive measurements can be calculated as ratio of the baseline motility. We further 
adjusted for time if a sample was not correctly measured at the respective time-point. To adjust for delay, the 
decay of motility over time was calculated to receive a corrected motility count (Form. 1).
= + − ∗
−
−
M M C B M M
A B
( )C B B A
Formula 1. Time correction for motility analysis. To compare for one defined time point, motility counts can 
be adapted by this formula accounting for the linear decrease in function. (A: time point at the measurement; B: 
time point before the measurement; C: time point to be calculated for; all in minutes) (MA: motility at the meas-
urement; MB: motility before the measurement; MC: motility to be calculated for; all in motile cells per minute).
Viability analysis. A cell staining technique applied in human fertility testing was adapted to our method28. 
30 µl semen was diluted (1:1) with cellular stains Eosin and Nigrosin (VitalStain™, Nidacon Int., Mölndal, 
Sweden) for 30 sec. A smear on a glass slide was performed and dried for at least 60 min. Oil immersion micros-
copy with 1000 × magnification was applied for analysis. Nigrosin served as enhancer of cellular contrast. Via 
light microscopy, Eosin+ dead could be identified by cytoplasmic incorporation of the red color (Fig. 4d). 100 
cells were manually counted, and eventually, survival readout was calculated as the absolute number of Eosin+ 
dead per 100 cells. Calculation were performed six times within different fields of the slide.
Preparation of uremic substances and patient serum. Uremic ultrafiltrate (UUF). UUF was col-
lected during hemodialysis with high flux membranes (FX80, Fresenius Medical Care, Bad Homburg, Germany) 
from five patients. Since ultrafiltration procedure (and no dialysis) was applied, UUF was not diluted. After 
filtration, UUF constitutes smaller sized substances in the same concentration present in blood36. Further, the 
ultrafiltrates were mixed and chromatographed to desalt, concentrate and fractionate the filtrate. For the chro-
matography, a preparative reversed phase C18 column was used as previously described36 which resulted into 
six fractions with increasing hydrophobicity (F1→F6). Eluted UUF was frozen at −80 degrees. In a next step, 
thawed UUF was applied 1:1 with semen (1:1 dilution of UUF; high concentration). In addition, thawed UUF was 
pre-diluted 1:8 with PBS and added 1:1 to the semen (1:16 dilution of UUF; low concentration). We replicated at 
least two non-toxic controls with cells from the same donation. For this, 100% PBS was applied.
Uremic toxin mix (UTM; Purine mixture). A mixture of purine substances was prepared containing uric acid, 
xanthine, uridine and uracil. For dissolving, NaOH and further addition of Tris buffer was used to reach a final pH 
of 7.4 to 7.741. The highest concentration of uremic toxins that was reported in uremic patients was applied2,3,38,42. 
For this, they are referred to as maximum concentration (Cmax). Before incubation, doubled Cmax-stock solutions 
were prepared to apply 1:1 dilution with the semen sample. This eventually resulted in a 1x Cmax -concentration 
in-vitro for uric acid (147 µg/ml), xanthine (3.44 µg/ml), uridine (32.6 µg/ml) and uracil (0.45 µg/ml). To test for 
dose-dependency, UTM was applied in a low concentration (Clow). For this, UTM was diluted 1:8 with PBS and 
applied 1:1 to the semen sample resulting in a 1:16 dilution of Cmax. For all toxins, we applied controls that were 
semen samples with a non-toxic medium (PBS). The control conditions were replicated four times and run in 
parallel to the toxic conditions.
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Single uremic substances. 47 uremic toxins (17 small water-soluble compounds (SWS), 16 protein bound (PB) 
and 14 middle molecules (MM)) were applied in Cmax2,3,38,42. For this, we pre-diluted the stock of toxins exten-
sively with PBS to achieve 2 × Cmax-level. In a next step, we added the pre-diluted toxin 1:1 to the semen to achieve 
1 × Cmax2,3,38,42 in-vitro. For individual Cmax of substances see Table 1. The toxins are listed here in order of the 
number represented in Fig. 4a: (SWS 1: guanidine, 2: malondialdehyde, 3: 1-methyladenosine, 4: taurocyamine, 
5: methylguanidine, 6: cytidine, 7: urea, 8: orotidine, 9: N-acetylarginine, 10: uric acid, 11: symmetric dimethyl 
arginine (SDMA), 12: 1-methylguanosine, 13: oxalate, 14: uracil, 15: hypoxanthine, 16: guanidinoacetic acid, 17: 
β-guanidinopropionic acid), (PB 18: leptin, 19: kynurenine, 20: kynurenic acid, 21: methylglyoxal, 22: phenyl sul-
fate, 23: 2-methoxyresorcinol, 24: 3-deoxyglucusone, 25: homocysteine, 26: p-OH-hippuric acid, 27: putrescine, 28: 
indoxyl glucuronide, 29: p-cresyl glucuronide, 30: phenyl glucuronide, 31: indoxyl sulfate, 32: p-cresol, 33: p-cresyl 
sulfate), (MM 34: Interleukin (IL)-6, 35: hyaluron, 36: IL-1β, 37: β-endorphin, 38: neuropeptide-γ, 39: Κ-Ig light 
chain, 40: retinol binding protein, 41: adrenomedullin, 42: tumor necrosis factor(TNF)-α, 43: endothelin, 44: atrial 
natriuretic peptide (ANP), 45: Lambda-Ig light chain, 46: complement factor D, 47: cholecystokinine). P-cresyl 
sulfate and phenyl sulfate were synthesized according to Feigenbaum and Neuberg as potassium salt48. P-cresyl glu-
curonide was synthesized from glucuronyl-trichloracetimidate and p-cresol using a protocol adapted from Van der 
Eycken and colleagues49. All remaining substances including indoxyl-β-D-glucuronide cyclohexylammonium salt, 
indoxyl sulfate potassium salt, potassium chloride, ammonium chloride and cyclohexammonium were purchased 
from Sigma-Aldrich Co, St. Louis, MO, USA.
Drug. Soluble furosemide (Nycomed, So4lna, Sweden) was applied in concentration calculated to the following 
formula: (medication dose given per day: 1 mg)/[0.6 (distribution volume) × body weight: 100 kg]. This resulted in 
an estimated in-vitro concentration of 166.7 µg/ml that was applied for in-vitro culture. Similar plasma levels were 
observed when furosemide was applied to ESKD patients50. To test for in-vitro dose-dependency, furosemide was 
further applied in a 1:4 dilution (1 × drug to 4 × PBS; Clow) and additionally, applied in a 10x concentration of 
Cnorm as Chigh. This resulted into in-vitro concentrations: Chigh: 1666,7 µg/ml, Cnorm: 166,7 µg/ml, Clow: 41,7 µg/ml.
Patient serum. Whole blood samples of patients were centrifuged at 1000 g for five minutes at room temper-
ature in serum separating tubes and subsequently, serum was transferred into a new vial. Incubation of serum was 
performed 1:1 with ex-vivo gained semen.
Statistics. Non-parametric paired comparisons were used by Wilcoxon analysis. Mann Whitney test was 
used for group comparison. Tests were calculated via IBM statistic software SPSS version 22 and a p-value of 
<0.05 was considered to be significant. Mean and standard deviations are presented throughout, unless otherwise 
indicated. R 3.5.1 coding software was applied to create the heat map. Overleaf v2 software was used to create 
initial graphical display of the mathematical formula. For all remaining graphs, Graph pad prism version 8.0.2 
was used.
Data Availability
The authors declare that all data supporting the findings of this study are available within the paper.
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